SUMMARY To evaluate the influence of oral verapamil (80 and 120 mg) on angina threshold, coronary blood flow, myocardial oxygen consumption and left ventricular function, we subjected 13 patients with effort angina and fixed obstructive coronary artery disease to atrial pacing at progressively higher heart rates. After 120 mg of verapamil, the time to onset of angina and the heart rate at the onset of ST-segment depression increased by 18% (p < 0.005) and 10% (p < 0.001), respectively, without any change in the angina threshold (rate-pressure product at the onset of angina). The rate-pressure product, coronary blood flow and myocardial oxygen consumption were lower at rest and at pre-angina heart rates but not when the angina threshold was reached. Thus, the beneficial effect of verapamil was primarily due to decreased myocardial oxygen demand rather than to increased coronary blood flow. The decreased demand resulted from a lower arterial pressure at each pacing rate. In these patients without heart failure, left ventricular pump function did not deteriorate. This beneficial response was less with 80 mg of oral verapamil. These findings suggest that oral verapamil has a potential role in the management of patients with effort angina due to fixed obstructive coronary artery disease.
VERAPAMIL is effective in the treatment of vasospastic angina.' Because of its potential to decrease myocardial oxygen demand as well as to increase coronary blood flow,2-5 its use has also been advocated for the management of stable angina in patients with fixed obstructive coronary artery disease. Although clinical benefit from long-term oral verapamil therapy has been reported,3'-the mechanisms for relief of angina after oral therapy in these patients have not been elucidated. In this study we determined the influence of oral verapamil on coronary and systemic hemodynamics, myocardial metabolism and angina threshold during atrial pacing in patients with fixed obstructive coronary artery disease.
Materials and Methods
Thirteen patients (seven males and six females) with stable angina that responded poorly to 13 blockers and nitrates were selected for the study. The patients were 48-81 years old and had had angina for 6 months to 8 years. Five patients had a remote myocardial infarction. In all patients, the coronary anatomy was known from selective coronary arteriograms. Significant obstructive lesions (D 50% stenosis) involving the left anterior descending, left circumflex, and right coronary arteries were present in six patients, left anterior descending and left circumflex arteries in three, and the left anterior descending and right coronary arteries in three. One patient had a lesion of the left anterior descending artery only. Twelve of the 13 patients were taking propranolol (160-320 mg) and all were taking nitrates (isosorbide dinitrate [Isordil] , 80-400 mg/ day). Propranolol was discontinued 5 days and nitrates 12 hours before the study.
Each patient gave informed, written consent. The right side of the heart was catheterized with a flow- the pacing rates of 90 and 110 beats/min and at the angina rate. The onset of electrocardiographic evidence of myocardial ischemia was determined by recording a precordial electrogram (V5) during the third minute of each 3-minute pacing period. After the pre-verapamil angina heart rate was determined, patients received 80 mg of verapamil orally. Seventy-five to 90 minutes after the oral dose, systemic and coronary hemodynamics and metabolic measurements were repeated at the control heart rate, then at pacing rates of 90 and 110 beats/min and at the preverapamil angina rate. In patients who did not have angina at the pre-verapamil angina heart rate, the pacing rate was further increased by 10 beats every 3 minutes until angina developed or a maximal pacing rate of 150 beats/min was reached. On the second day, the above sequence was repeated after 120 mg of oral verapamil.
Statistical Analysis
The variables measured after 80 and 120 mg of verapamil were compared with the corresponding variables obtained during the control pacing immediately before each dose by a two-tailed, paired t test.
Results

Systemic Hemodynamics
Changes in systemic hemodynamics after 80 and 120 mg of oral verapamil at the control heart rate and during supraventricular pacing are summarized in table 1. There was no significant change in control heart rate, pulmonary capillary wedge pressure or cardiac index after 80 and 120 mg of verapamil. Mean arterial pressure and stroke work index decreased after both the 80-and 120-mg doses. Systemic vascular resistance and arterial diastolic pressure decreased significantly only after the 120-mg dose. During pacing at the pre-angina heart rates of 90 and 110 beats/min, no significant changes in systemic hemodynamics were observed after 80 mg of verapamil except for a lower arterial pressure at 90 beats/min and a lower stroke work index at 110 beats/min.
Changes in systemic hemodynamics were relatively more pronounced after 120 mg of oral verapamil. Thus, there was a consistent and statistically significant decrease in arterial mean and diastolic pressures at the pre-angina pacing rates of 90 and 110 beats/min. Pulmonary capillary wedge pressure and systemic vascular resistance were generally lower, although cardiac index remained unchanged. Thus, the stroke work index at 110 beats/min after verapamil was less than that before verapamil at the same heart rate.
At the pre-verapamil angina heart rate after 80 mg of verapamil, arterial mean and diastolic pressures, pulmonary capillary wedge pressure, stroke work index, and systemic vascular resistance did not change significantly. After the 120-mg dose, however, arterial mean and diastolic pressures, pulmonary capillary wedge pressure and systemic vascular resistance were After 80 mg of verapamil, there was no significant increase in the duration of pacing before the onset of angina and the heart rate at the onset of ST-depression was not significantly different from control. With 120 mg of verapamil, however, there was a significant increase in the pacing time before the onset of angina, and three patients did not have angina after verapamil even at the maximal pacing rate. The heart rate at the onset of ST-segment depression after the 120-mg dose was significantly higher than that before verapamil (table 2) .
Coronary Hemodynamics (table 3) Coronary sinus flow was determined in all 13 patients, and arterial-coronary sinus oxygen difference, myocardial oxygen consumption and lactate extraction = systemic vascular resistance.
were determined in 12 patients. After 90 mg of verapamil, the rate-pressure product ( fig. 1) , coronary sinus flow ( fig. 2 ) and myocardial oxygen consumption ( fig. 3 ) decreased at rest and at the pre-angina pacing rates of 90 and 110 beats/min. At the preverapamil angina rate, the rate-pressure product, coronary sinus flow and myocardial oxygen consumption did not change.
After 120 mg of verapamil, the rate-pressure product ( fig. 1), coronary sinus flow (fig. 2 ) and myocardial oxygen consumption ( fig. 3 ) decreased significantly at rest and at the pacing rates of 90 and 110 beats/min. The rate-pressure product, coronary sinus blood flow and myocardial oxygen consumption were also lower at the pre-verapamil angina heart rate. However, in 10 patients who had angina after 120 mg of verapamil, the rate-pressure product at the onset of angina was not different from that before verapamil (20.2 + 4.9 vs 19.2 ± 4.7 x 10-3), indicating no change in angina threshold in these patients. Similarly, coronary sinus The present study suggests that decreased myocardial oxygen demand is the principal mechanism by which verapamil produces its beneficial effects in patients with pacing-induced angina due to fixed obstructive coronary artery disease. After verapamil, the ratepressure product, an index of myocardial oxygen demand, was lower not only at rest and pre-angina pacing rates but also at the pre-verapamil angina rate. Because of the lower rate-pressure product, the duration of pacing before the onset of angina was longer and the onset of ST-segment depression was delayed in our patients. The rate-pressure product, coronary sinus flow and myocardial oxygen consumption all decreased. Thus, reduction in myocardial oxygen demand and oxygen consumption appeared to be the principal factors by which verapamil produced its beneficial effects. In this respect, verapamil appears to be similar to other effective antianginal agents such as nitrates.
The rate-pressure product decreased primarily due to a fall in arterial pressure, a well documented systemic hemodynamic effect of verapamil. 2 19 22 In this study, changes in heart rate could not be evaluated, for VERAPAMIL 80 mg heart rate was controlled by atrial pacing. Verapamil, however, also has the potential to decrease heart rate by its effect on cardiac conduction tissues. A lower heart rate may further reduce myocardial oxygen demand and might help relieve effort angina.23 Verapamil also exerts a negative inotropic effect, which should further decrease myocardial oxygen demand. Our patients showed no significant change in left ventricular systolic function after verapamil, and left ventricular filling pressures remained unchanged. However, a lack of deterioration in left ventricular pump function in our patients does not rule out a possible negative inotropic effect. Systemic vascular resistance was significantly reduced, which would improve left ventricular pump function by decreasing ejection impedance. Therefore, the negative inotropic effect of verapamil might have been balanced by the concomitant decrease in left ventricular ejection impedance.
The effectiveness of verapamil in relieving effort and pacing-induced angina has been reported. Pine 
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F effect was primarily due to a reduction in arterial pressure. In the absence of clinical heart failure, oral verapamil did not cause any deterioration in left ventricular pump function.
